ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer (NCT02688712)
Phase II Study of TGFฮฒ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this study, research will be done on tumor samples to see if it is possible to predict if patients will respond to treatment, and blood samples to look at the immune system response to study treatment. About 50 people will take part in this study. The study treatment will be given over an 8 week period and the investigators will continue to collect your health information for up to 5 years, as part of this study
Who can join: Review the eligibility criteria below.
Location: Providence Cancer Center โ Portland, Oregon
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Providence Cancer Center โ Portland, Oregon
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rectal Adenocarcinoma
- Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma โ Tampa, Florida
- ctDNA-Informed Management of Early-Stage Rectal Cancer โ Sacramento, California
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors โ Hartford, Connecticut
- Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer โ Houston, Texas
- Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer โ Portland, Oregon
Explore by condition: All Rectal Adenocarcinoma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.